Revvity Inc. (NYSE:RVTY – Get Free Report) CAO Anita Gonzales sold 84 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $155.48, for a total value of $13,060.32. Following the sale, the chief accounting officer owned 7,117 shares in the company, valued at $1,106,551.16. The trade was a 1.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Anita Gonzales also recently made the following trade(s):
- On Monday, July 20th, Anita Gonzales sold 85 shares of Revvity stock. The stock was sold at an average price of $109.48, for a total value of $9,305.80.
Revvity Trading Up 1.6%
NYSE RVTY traded up $2.40 on Friday, hitting $151.46. 1,235,180 shares of the stock were exchanged, compared to its average volume of 1,499,707. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. Revvity Inc. has a 52-week low of $81.22 and a 52-week high of $158.28. The firm has a market capitalization of $16.90 billion, a P/E ratio of 72.13, a P/E/G ratio of 2.78 and a beta of 1.06. The stock has a fifty day moving average price of $127.45 and a two-hundred day moving average price of $108.40.
Revvity Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity’s dividend payout ratio is presently 13.33%.
Wall Street Analyst Weigh In
RVTY has been the subject of several analyst reports. UBS Group assumed coverage on shares of Revvity in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $140.00 price objective for the company. Weiss Ratings upgraded Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 30th. Evercore reiterated an “outperform” rating on shares of Revvity in a report on Wednesday, August 5th. Sanford C. Bernstein assumed coverage on Revvity in a research note on Friday, June 26th. They set a “market perform” rating and a $115.00 price target for the company. Finally, TD Cowen restated a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Four equities research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $116.57.
View Our Latest Report on Revvity
Institutional Investors Weigh In On Revvity
Several large investors have recently added to or reduced their stakes in RVTY. Jupiter Topco LLC purchased a new position in shares of Revvity during the second quarter worth approximately $961,017,000. BlackRock Inc. purchased a new stake in shares of Revvity in the second quarter valued at approximately $852,070,000. Janus Henderson Group PLC grew its stake in Revvity by 7.0% in the fourth quarter. Janus Henderson Group PLC now owns 8,161,171 shares of the company’s stock worth $789,595,000 after purchasing an additional 533,912 shares in the last quarter. EdgePoint Investment Group Inc. grew its stake in Revvity by 3.1% in the first quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company’s stock worth $771,044,000 after purchasing an additional 265,204 shares in the last quarter. Finally, State Street Corp increased its holdings in Revvity by 0.8% during the 2nd quarter. State Street Corp now owns 4,342,739 shares of the company’s stock worth $483,173,000 after purchasing an additional 32,426 shares during the period. 86.65% of the stock is owned by hedge funds and other institutional investors.
About Revvity
Revvity, Inc (NYSE:RVTY) is a life sciences and diagnostics company that provides technologies, products and services used in biological research, drug discovery, clinical testing and healthcare. The company serves pharmaceutical and biotechnology companies, academic and government research institutions, hospitals, clinical laboratories and other healthcare organizations.
Its portfolio includes instruments, reagents, consumables, software and related services for areas such as genomics, proteomics, cellular analysis, imaging and multiplex testing.
Recommended Stories
- Five stocks we like better than Revvity
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
